美国 · SEC FORM 4
Syndax Pharmaceuticals Inc
SNDX · Nasdaq · CIK 0001395937 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
8 同一窗口内观察到的 Form 4 交易行
5 sales · 3 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-05-19 · Goldan Keith A..
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 18,234,880
- 上期报告
- 20,660,449
- 日均成交量
- 2,152,633
- 回补天数
- 8.5
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-05-19 | Katkin Keith | 买入 (P) | Common Stock | 10,000 | USD 9.11 | USD 91,100 | SEC 申报 ↗ |
| 2025-05-19 | Huber Martin H. Jr. | 买入 (P) | Common Stock | 5,000 | USD 8.99 | USD 44,950 | SEC 申报 ↗ |
| 2025-05-19 | Goldan Keith A. | 买入 (P) | Common Stock | 3,000 | USD — | USD — | SEC 申报 ↗ |
| 2025-05-16 | Botwood Nicholas A.J. | 买入 (P) | Common Stock | 11,765 | USD 9.00 | USD 105,885 | SEC 申报 ↗ |
| 2024-06-14 | Goldan Keith A. | 买入 (P) | Common Stock | 1,250 | USD 20.03 | USD 25,038 | SEC 申报 ↗ |
| 2021-04-26 | Meyers Michael L. | 买入 (P) | Common Stock | 500 | USD 15.46 | USD 7,730 | SEC 申报 ↗ |
| 2021-04-22 | Podlesak Dennis | 买入 (P) | Common Stock | 13,967 | USD 14.11 | USD 197,074 | SEC 申报 ↗ |
| 2020-02-04 | Morrison Briggs | 买入 (P) | Common Stock | 12,500 | USD 8.00 | USD 100,000 | SEC 申报 ↗ |
Form 4 申报证据
26 transaction lines in the latest 365-day window; 293 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-07-08 | Metzger Michael A | 卖出 (S) | Common Stock | 32,375 | USD 24.24 | USD 784,770 | SEC 申报 ↗ |
| 2026-07-08 | Metzger Michael A | 期权行权／转换 (M) | Common Stock | 32,375 | USD 6.38 | USD 206,552 | SEC 申报 ↗ |
| 2026-06-12 | Botwood Nicholas A.J. | 卖出 (S) | Common Stock | 31,235 | USD 18.14 | USD 566,603 | SEC 申报 ↗ |
展开近期 Form 4 证据 (23 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-07-08 | Metzger Michael A | 卖出 (S) | Common Stock | 32,375 | USD 24.24 | USD 784,770 | SEC 申报 ↗ |
| 2026-07-08 | Metzger Michael A | 期权行权／转换 (M) | Common Stock | 32,375 | USD 6.38 | USD 206,552 | SEC 申报 ↗ |
| 2026-06-12 | Botwood Nicholas A.J. | 卖出 (S) | Common Stock | 31,235 | USD 18.14 | USD 566,603 | SEC 申报 ↗ |
| 2026-06-12 | Botwood Nicholas A.J. | 期权行权／转换 (M) | Common Stock | 31,235 | USD 13.82 | USD 431,668 | SEC 申报 ↗ |
| 2026-06-11 | Botwood Nicholas A.J. | 卖出 (S) | Common Stock | 34,280 | USD 18.00 | USD 617,040 | SEC 申报 ↗ |
| 2026-06-11 | Botwood Nicholas A.J. | 期权行权／转换 (M) | Common Stock | 22,515 | USD 13.82 | USD 311,157 | SEC 申报 ↗ |
| 2026-06-01 | Metzger Michael A | 卖出 (S) | Common Stock | 6,847 | USD 18.99 | USD 130,025 | SEC 申报 ↗ |
| 2026-06-01 | Goldan Keith A. | 卖出 (S) | Common Stock | 1,177 | USD 18.99 | USD 22,351 | SEC 申报 ↗ |
| 2026-02-09 | Metzger Michael A | 卖出 (S) | Common Stock | 17,159 | USD 21.03 | USD 360,854 | SEC 申报 ↗ |
| 2026-02-09 | Goldan Keith A. | 卖出 (S) | Common Stock | 3,410 | USD 21.03 | USD 71,712 | SEC 申报 ↗ |
| 2026-02-06 | Metzger Michael A | 卖出 (S) | Common Stock | 7,412 | USD 20.62 | USD 152,835 | SEC 申报 ↗ |
| 2026-02-06 | Goldan Keith A. | 卖出 (S) | Common Stock | 2,082 | USD 20.62 | USD 42,931 | SEC 申报 ↗ |
| 2026-02-04 | Rizo Aleksandra | 奖励／授予 (A) | Common Stock | 24,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-04 | Podlesak Dennis | 奖励／授予 (A) | Common Stock | 48,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-04 | Metzger Michael A | 奖励／授予 (A) | Common Stock | 217,600 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-04 | Legault Pierre | 奖励／授予 (A) | Common Stock | 24,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-04 | Katkin Keith | 奖励／授予 (A) | Common Stock | 24,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-04 | Jarrett Jennifer | 奖励／授予 (A) | Common Stock | 24,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-04 | Huber Martin H. Jr. | 奖励／授予 (A) | Common Stock | 24,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-04 | Goldan Keith A. | 奖励／授予 (A) | Common Stock | 52,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-04 | Botwood Nicholas A.J. | 奖励／授予 (A) | Common Stock | 60,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-30 | Goldan Keith A. | J (J) | Common Stock | 1,219 | USD 8.48 | USD 10,337 | SEC 申报 ↗ |
| 2025-12-01 | Goldan Keith A. | 赠与 (G) | Common Stock | 1,224 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | SNDX |
| CIK | 0001395937 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 293 transaction lines from 2020-01-31 to 2026-07-08 8 P purchase lines · 112 S sale lines · 173 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.